| Date | Title | Description | Source |
| 04.01.2024 | JW Therapeutics Announces NMPA Acceptance of the Supplementa... | SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative b... | en.prnasia... |
| 02.01.2024 | JW Therapeutics Announces Exclusive Collaboration with 2seve... | SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biote... | en.prnasia... |
| 10.04.2023 | JW Therapeutics Announces IND Approval for the Clinical Tria... | SHANGHAI, April 10, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative... | en.prnasia... |
| 30.03.2023 | JW Therapeutics Announces its Cell Immunotherapy Drugs Have ... | SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative... | en.prnasia... |
| 30.03.2023 | JW Therapeutics Announces its Cell Immunotherapy Drugs Have ... | SHANGHAI, March 29, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative... | einpresswi... |
| 08.03.2023 | JW Therapeutics Announces Initiation of Clinical Study of Ca... | SHANGHAI, March 8, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative ... | en.prnasia... |
| 28.02.2023 | JW Therapeutics Announces Initiation of Clinical Study of JW... | SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative ... | en.prnasia... |
| 12.12.2022 | JW Therapeutics Presents Latest Clinical Data on Carteyva® i... | SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative ... | en.prnasia... |
| 12.12.2022 | JW Therapeutics Presents Latest Clinical Data on Carteyva® i... | SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative ... | einpresswi... |
| 09.11.2022 | JW Therapeutics Announces its Cell Immunotherapy Drugs Have ... | SHANGHAI, Nov. 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative b... | en.prnasia... |
| 27.10.2022 | JW Therapeutics and 2seventy bio Announce Strategic Partners... | Initial focus on accelerating development of 2seventy's MAGE-A4 program in solid tumors in China
SH... | en.prnasia... |
| 10.10.2022 | JW Therapeutics Announces NMPA Approval of Relmacabtagene Au... | SHANGHAI, Oct. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative ... | en.prnasia... |
| 04.07.2022 | JW Therapeutics Announces Initiation of Clinical Study of JW... | SHANGHAI, July 4, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative b... | en.prnasia... |
| 05.06.2022 | JW Therapeutics Presents Latest Data of Carteyva® at 2022 AS... | SHANGHAI, June 5, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative b... | en.prnasia... |
| 09.05.2022 | JW Therapeutics to Present Latest Data of Carteyva® at 2022 ... | SHANGHAI, May 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative bi... | en.prnasia... |
| 25.04.2022 | JW Therapeutics Announces its Cell Immunotherapy Drugs Have ... | SHANGHAI, April 25, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative... | en.prnasia... |
| 20.04.2022 | JW Therapeutics Announces IND Approval for the Clinical Tria... | SHANGHAI, April 20, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative bi... | en.prnasia... |
| 03.04.2022 | JW Therapeutics Announces Receipt of Breakthrough Therapy De... | SHANGHAI, April 3, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative bio... | en.prnasia... |
| 31.03.2022 | JW Therapeutics Announces IND Approval for the Pivotal Clini... | SHANGHAI, March 31, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative bi... | en.prnasia... |
| 27.02.2022 | JW Therapeutics Announces NMPA Acceptance of the Supplementa... | SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative bio... | en.prnasia... |
| 10.01.2022 | JW Therapeutics Announces Two Appointments to Strengthen R&a... | SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative bio... | en.prnasia... |
| 15.12.2021 | JW Therapeutics Presents Primary Clinical Response on Cartey... | SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biot... | en.prnasia... |
| 27.09.2021 | JW Therapeutics Announces IND Approval for the Clinical Tria... | SHANGHAI, Sept. 27, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology c... | en.prnasia... |
| 26.09.2021 | JW Therapeutics Announces Updated 1-year Follow-up Result of... | SHANGHAI, Sept. 26, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology c... | en.prnasia... |
| 06.09.2021 | JW Therapeutics Announces NMPA Approval of Relmacabtagene Au... | The first CAR-T product independently developed in China and approved as a Category 1 biologics prod... | en.prnasia... |
| 20.08.2021 | JW Therapeutics Announces Strategic Partnership with MediTru... | SHANGHAI, Aug. 20, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology co... | en.prnasia... |
| 20.08.2021 | JW Therapeutics : Announces Strategic Partnership with MediT... | SHANGHAI, Aug. 20, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology co... | marketscre... |
| 07.12.2020 | JW Therapeutics Presents Data from Pivotal Trial of Relma-ce... |
SHANGHAI, Dec. 7, 2020 /PRNewswire/ -- JW Therapeutics (stock code: 2126.HK), a leading clinical s... | prnewswire... |
| 02.11.2020 | Leading Cell Therapy Company JW Therapeutics Lists on Main B... |
SHANGHAI, Nov. 2, 2020 /PRNewswire/ -- JW Therapeutics (stock code: 2126.HK), a leading clinical s... | prnewswire... |
| 26.07.2020 | JW Therapeutics Acquires Syracuse Biopharma | JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and... | finsmes.co... |
| 11.06.2020 | Juno, WuXi JV in China score $100M in fresh funding as it ... | China’s oncology-focused biotech hub has raised already millions in venture funding and lur... | endpts.com... |
| 10.06.2020 | Chinese biopharma firm JW Therapeutics nets $100m in Series ... | Premium
Chinese clinical-stage biopharmaceutical firm JW Therapeutics on Wednesday announced the co... | dealstreet... |
| 08.03.2018 | JW Therapeutics Raises $90M in Series A Financing | JW Therapeutics, a Shangai, China-based clinical stage biopharmaceutical company, completed a $90m S... | finsmes.co... |
